Aa
riba pkg insert (part 1) re. riba dose
I am GT 1 and my md only wants to give me 800 mg of riba because I weigh 115 lbs. Why ?!
•for the treatment of chronic hepatitis C infection (monoinfection) in combination with interferon alfa-2b in patients previously untreated with interferon alpha:
NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials (see Contraindications/Precautions).
NOTE: The American Association for the Study of Liver Diseases (AASLD) recommends a peginterferon alfa product in combination with ribavirin as the preferred therapy for chronic hepatitis C infection.[20505]
Oral dosage (capsules or oral solution):
Adults > 75 kg: 600 mg PO twice daily (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week for 24—48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. There are no safety or efficacy data on treatment longer than 48 weeks.[29161]
Adults 73 kg: 15 mg/kg/day PO or 1200 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks. NOTE: The manufacturer does not provide a specific maximum dosage for pediatric patients; however, for this indication, the maximum dosage for adults weighing > 75 kg is 1200 mg/day.[29161]
Children and Adolescents 62—73 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 60—61 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 47—59 kg: 15 mg/kg/day PO or 800 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents >= 3 years and < 47 kg: 15 mg/kg/day PO divided twice daily plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Neonates, Infants, and Children 75 kg: 600 mg PO twice daily (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week for 24 weeks. There are no safety or efficacy data on treatment longer than 24 weeks.[29161]
Adults 73 kg: 15 mg/kg/day PO or 1200 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks. NOTE: The manufacturer does not provide a specific maximum dosage for pediatric patients; however, for this indication, the maximum dosage for adults weighing > 75 kg is 1200 mg/day.[29161]
Children and Adolescents 62—73 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 60—61 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 47—59 kg: 15 mg/kg/day PO or 800 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents >= 3 years and < 47 kg: 15 mg/kg/day PO divided twice daily plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Neonates, Infants, and Children < 3 years: Safety and efficacy have not been established.
•for the treatment of chronic hepatitis C infection (monoinfection) in combination with interferon alfa-2b in patients previously untreated with interferon alpha:
NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials (see Contraindications/Precautions).
NOTE: The American Association for the Study of Liver Diseases (AASLD) recommends a peginterferon alfa product in combination with ribavirin as the preferred therapy for chronic hepatitis C infection.[20505]
Oral dosage (capsules or oral solution):
Adults > 75 kg: 600 mg PO twice daily (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week for 24—48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. There are no safety or efficacy data on treatment longer than 48 weeks.[29161]
Adults 73 kg: 15 mg/kg/day PO or 1200 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks. NOTE: The manufacturer does not provide a specific maximum dosage for pediatric patients; however, for this indication, the maximum dosage for adults weighing > 75 kg is 1200 mg/day.[29161]
Children and Adolescents 62—73 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 60—61 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 47—59 kg: 15 mg/kg/day PO or 800 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents >= 3 years and < 47 kg: 15 mg/kg/day PO divided twice daily plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Neonates, Infants, and Children 75 kg: 600 mg PO twice daily (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week for 24 weeks. There are no safety or efficacy data on treatment longer than 24 weeks.[29161]
Adults 73 kg: 15 mg/kg/day PO or 1200 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks. NOTE: The manufacturer does not provide a specific maximum dosage for pediatric patients; however, for this indication, the maximum dosage for adults weighing > 75 kg is 1200 mg/day.[29161]
Children and Adolescents 62—73 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units SC/IM 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 60—61 kg: 15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents 47—59 kg: 15 mg/kg/day PO or 800 mg/day PO given in 2 divided doses (in the morning and evening) plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Children and Adolescents >= 3 years and < 47 kg: 15 mg/kg/day PO divided twice daily plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.[29161]
Neonates, Infants, and Children < 3 years: Safety and efficacy have not been established.
Hi I am having the same question as you are, I am 140 lbs 5' 5" and my prescription is for riba 800 mg and 120 for pegintron, I am worried it is too little so am calling the doc on Monday
In 2008 I also took 1000 Riba and 180 Pegasys maybe with the third drug it is not as important but I want to check. I want to get to SVR this time
Thanks for the question
Dee
In 2008 I also took 1000 Riba and 180 Pegasys maybe with the third drug it is not as important but I want to check. I want to get to SVR this time
Thanks for the question
Dee
Hi everyone, went to see the doctor this morning. I weigh 74kg as of this morning. The doctor agree to up my dosage another 200 mg to 1200 mg. I am in my 16 week. She also agree that i should do my best to get the virus cleared on this treatment. I will be seeing her again next week to check the blood count.Thanks again everyone.
thanks all. I started to worry about this. I called the NP and got upset on the phone - and I haven't even started tx yet. They probably will want to put me on anti-depressants ;)
Well...my doctor was involved with incevik trials and he says that my riba dose should be 800 mg per day. I will try to gather info to support the 1000 mg dose. And as a last resort, I am still thinking about taking an extra 200 mg ( my left -over riba pills from 2008) until i at least reach und.
Well...my doctor was involved with incevik trials and he says that my riba dose should be 800 mg per day. I will try to gather info to support the 1000 mg dose. And as a last resort, I am still thinking about taking an extra 200 mg ( my left -over riba pills from 2008) until i at least reach und.
"200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg "
Good find spectda, sense this is the dose they used in the trials to get the svr results, i would want nothing less.
Good find spectda, sense this is the dose they used in the trials to get the svr results, i would want nothing less.
"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 HCV
http://clinicaltrials.gov/ct2/show/NCT00627926?term=telaprevir&rank=17
Biological: peginterferon alfa-2a
subcutaneous injection, 180 micrograms once per week
Other Name: Pegasys, Peg-IFN
Drug: telaprevir
375 mg tablets administered orally every 8 hours at a dose of 750 mg
Other Name: TVR, VX-950
Drug: ribavirin
200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
Other Name: Copegus, RBV"
http://clinicaltrials.gov/ct2/show/NCT00627926?term=telaprevir&rank=17
Biological: peginterferon alfa-2a
subcutaneous injection, 180 micrograms once per week
Other Name: Pegasys, Peg-IFN
Drug: telaprevir
375 mg tablets administered orally every 8 hours at a dose of 750 mg
Other Name: TVR, VX-950
Drug: ribavirin
200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
Other Name: Copegus, RBV"
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
